FDA Approves Combination Therapy for Muscle-Invasive Bladder Cancer

The U.S. Food and Drug Administration (FDA) has approved a combination of enfortumab vedotin and pembrolizumab for treating adults with muscle-invasive bladder cancer. This new treatment option is for patients eligible for cystectomy, regardless of their cisplatin eligibility. The approval expands therapeutic choices for individuals facing this aggressive cancer, offering new hope.